



## **Coviu and ResApp Health Sign Service Agreement to Use ResAppDx-EU on Coviu's Telehealth Platform**

**Brisbane, Australia, 1 July 2020** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Coviu Global Pty Ltd, Australia's leading telehealth platform provider, have signed a service agreement to make ResApp's acute respiratory diagnostic test, ResAppDx-EU available through Coviu's web-based telehealth platform. ResAppDx-EU is approved by the Therapeutics Goods Administration (TGA) in Australia and is CE Marked in Europe as an aid for clinicians in the diagnosis of a range of respiratory diseases.

The two-year, non-exclusive commercial agreement allows ResApp to provide ResAppDx-EU to customers of the Coviu platform within Australia. The per test license fee paid to ResApp is in the previously targeted range of \$5 to \$10. The agreement may be extended beyond the initial two-year term by mutual agreement and either party may terminate the licence by providing 60 days written notice.

A spinout from CSIRO's Data61, Coviu's telehealth platform makes it easy for healthcare providers to offer their services directly to patients via video consultation whilst incorporating a range of digital assessment tools to assist in virtual consults. The Coviu platform has over 22,000 active health professionals using the service.

"We are pleased to have worked closely with Coviu to provide ResAppDx-EU to Australian clinicians via Coviu's platform," said Tony Keating, CEO and Managing Director of ResApp. "Respiratory symptoms are among the most common reasons for patients to request a telehealth consultation and for the first time clinicians on Coviu's platform will have an accurate way of assessing those symptoms remotely."

The ResAppDx Coviu Add-On will be available to Coviu's customers on 9 July when Coviu completes their next scheduled platform update. The initial launch release will be available to patients using iPhones, while all platforms (mobile and desktop) are supported on the clinician side. An Android version for patients will be available later this year.

###

### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx-EU, a smartphone-based acute respiratory disease

**ResApp Health Limited** ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T +61 7 3724 0035 E [info@resapphealth.com.au](mailto:info@resapphealth.com.au) W [www.resapphealth.com.au](http://www.resapphealth.com.au)



diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

#### **About Coviu Global Pty Ltd**

Coviu Global Pty Ltd is Australia's leading telehealth software company and a spinout of CSIRO's Data61, offering a video consultation software to healthcare businesses. It brings the specific workflows and tools necessary for healthcare into an online video call while satisfying regulatory requirements around security and privacy. For more information, please visit [www.coviu.com](http://www.coviu.com).

#### **Contacts for ResApp Health**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

#### **Contacts for Coviu Global**

Dr Silvia Pfeiffer  
CEO  
+61 401 384 041  
[silvia.pfeiffer@coviu.com](mailto:silvia.pfeiffer@coviu.com)

Natascha Kwiet-Evans  
Mojo Media  
+61 405 166 566  
[natascha.kwietevans@mojomedial.com.au](mailto:natascha.kwietevans@mojomedial.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*